



## PERFORMANCE UPDATE

## 1H 2024

# 01

## Company Overview




# IDR 367,8 Billion

1H 2024 Revenue (-33,7% yoy)



# IDR (49,8) Billion

1H 2024 Net Income for the Period (-743,6% yoy)




# 5 SKUs

*(set to be launched for 2024)*

- Established in **1954** with more than **250 products** available in the market
- **Antimo** continues to be **the market leader** among competitors, dominating over **70% market share** in Antiemetic & Anti-Nausea treatment
- One of few Pharmaceutical Manufacturing Industries with **Certified Calibration Laboratory**



## Shareholder Composition



## Phapros' Leading Products



**OTC**



**GENERIC**



**ETHICAL**



**Antimo Group**



**Tablet Tambah Darah**



**Dexamine**



**Livron B Plex**



**Omeprazole**



**Pro TB Group**



**Noza**



**Dexamethasone**



**Pehacain**





02




## Market Overview



## Indonesia Economic Outlook

# GDP Growth Projection for 2024



**4,8 – 5,7%**



**World Bank** : 4,9%



**OECD** : 5,1%



**IMF** : 4,8%



**ADB** : 5,0%

*A modest acceleration in real GDP growth is anticipated due to the easing of inflation and interest rates in 2024, which will stimulate household spending.*

*Bank Indonesia, is expected to implement a more relaxed monetary policy in the latter half of the same year, further bolstering economic growth.*



## Indonesia Pharmaceutical Market Overview



Total Market Value  
126,234 bio



Growth MAT: -0.1%  
Growth QTR: 0.5%



*Despite a minuscule decline in total pharmaceutical market value, the Ethical segment continued to show positive growth*






# 03




## Performance Highlight

## Corporate Event Highlights



In pursuit of our aspiration to be the foremost pharmaceutical company, Phapros continues to earn various accolades throughout the first half of the year

## Financial Update



Despite experiencing a significant decline in both Profit and EBITDA, Phapros remains dedicated to achieving maximum results in 2024.






# 04

## Business Strategy

## Grand Strategy 2024



**BUMI** UNTUK  
INDONESIA

**Phapros**

**THANK YOU**  
**STAY HEALTHY**

**MANUFACTURING PLANT**

**PT PHAPROS TBK**  
Jl. Simongan No 131  
Semarang 50148 INDONESIA  
Phone : (62-24) 762 5484

**HEAD OFFICE**

**PT PHAPROS TBK**  
Menara Rajawali Lantai 17  
Jl. DR Ide Anak Agung Gde Agung  
Mega Kuningan JAKARTA 12950 INDONESIA  
Phone : +62 21 576 2709 | Fax : +62 21 576 3910



Phapros



phapros.id



PTPhapros



PT Phapros Tbk



www.phapros.co.id

**AKHLAK**

**AMANAH**

**KOMPETEN**

**HARMONIS**

**LOYAL**

**ADAPTIF**

**KOLABORATIF**